When Pandemics Collide: the Interplay of Obesity and COVID-19.
Manpreet S MundiJayshil J PatelOsman Mohamed ElfadilJalpan PatelIshani PatelSanjeev NandaRyan T HurtPublished in: Current gastroenterology reports (2021)
Obese individuals through a combination of structural and cellular level changes have greater risk of ischemic heart disease, diabetes, cancer, and respiratory disease, which are themselves risk-factors for acquiring COVID-19 disease. These structural changes also result in increased intra-abdominal and intra-thoracic pressure as well as a restrictive lung physiology that leads to reduction in total lung capacity, functional residual capacity, and increase in airway hyper-reactivity. Adipose tissue is also impacted in obese individuals leading to local as well as systemic inflammation, which can contribute to increased release of free fatty acids and systemic insulin resistance. Additionally, angiotensin-converting enzyme 2 and dipeptidyl peptidase 4, which act as receptors for SARS-CoV-2 are also significantly increased in obese individuals. The present manuscript reviews these structural, immune, and molecular changes associated with obesity that make obese individuals more vulnerable to acquiring severe COVID-19 and more challenging to manage associated complications.
Keyphrases
- adipose tissue
- insulin resistance
- sars cov
- metabolic syndrome
- weight loss
- type diabetes
- coronavirus disease
- high fat diet
- high fat diet induced
- angiotensin converting enzyme
- respiratory syndrome coronavirus
- bariatric surgery
- polycystic ovary syndrome
- glycemic control
- obese patients
- angiotensin ii
- cardiovascular disease
- spinal cord
- fatty acid
- squamous cell carcinoma
- papillary thyroid
- randomized controlled trial
- early onset
- lymph node metastasis
- single molecule